A new treatment option for stage IIIB lung squamous cell carcinoma-Hypofractionated brachytherapy combined with ICIs: A Case Report

Here, we present a case of a patient with stage IIIB squamous lung cancer with mediastinal and cervical lymph node metastases in the left lung with peripheral squamous lung cancer, who was selected for simultaneous immunotherapy with insertional radiotherapy at the primary site in the left lung, followed by intensity-modulated radiotherapy for mediastinal and cervical lymph node metastases and maintenance immunotherapy every 3 weeks. There was no treatment-related toxicity above grade 2 during the treatment. The response was PR, and PFS was more than 12 months. That provides a new therapeutic idea for treating advanced squamous lung cancer.